Mechanism of action
Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but does not interact with GABA receptors, nor is it converted into GABA or a GABA agonist. Instead, gabapentin binds with high affinity to the α2δ-1 subunit of voltage-gated calcium channels in the central nervous system.
By binding to this auxiliary subunit, gabapentin reduces calcium influx at presynaptic nerve terminals, thereby decreasing the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. This reduction in excitatory transmission is particularly relevant in hyperexcitable states such as neuropathic pain and epilepsy.
The α2δ-1 subunit is upregulated in dorsal root ganglia and spinal cord after nerve injury, which may explain gabapentin's efficacy in neuropathic pain conditions. The drug modulates neuronal excitability without directly affecting normal neurotransmission, providing a favorable therapeutic window.
Gabapentin does not bind to other common drug targets such as benzodiazepine, opioid, or cannabinoid receptors, and it does not inhibit GABA uptake or degradation.
- Gabapentin binds α2δ-1 subunit of voltage-gated calcium channels, NOT GABA receptors despite being a GABA analog
- Eliminated exclusively by renal excretion unchanged; requires dose adjustment in renal impairment
- Bioavailability is dose-dependent due to saturable L-amino acid transporter; decreases with higher doses
- No hepatic metabolism and minimal protein binding result in few drug-drug interactions
- Antacids reduce absorption by 20%; take gabapentin 2 hours after antacids
- Must taper gradually to avoid withdrawal seizures, even in patients without epilepsy
- Combined use with opioids increases risk of respiratory depression (FDA warning 2019)
- FDA-approved for postherpetic neuralgia and adjunctive therapy for partial seizures
Indications
FDA-approved indications for gabapentin include:
- Postherpetic neuralgia in adults
- Adjunctive therapy for partial seizures with and without secondary generalization in patients 3 years and older
- Adjunctive therapy for partial seizures in pediatric patients 3-12 years of age
Common off-label uses include:
- Diabetic peripheral neuropathy
- Fibromyalgia
- Neuropathic pain of various etiologies
- Restless legs syndrome
- Hot flashes
- Alcohol withdrawal symptoms
- Migraine prophylaxis
Gabapentin has become widely prescribed for chronic pain conditions, though evidence quality varies by indication. It is not a first-line agent for generalized anxiety disorder or bipolar disorder despite some off-label use in these conditions.
Pharmacokinetics
Absorption
Gabapentin is absorbed via the L-amino acid transporter system in the gut, which is a saturable transport mechanism. Bioavailability decreases with increasing dose: approximately 60% at 900 mg/day, declining to 35% at 3600 mg/day. Food slightly increases the rate and extent of absorption.
Distribution
Gabapentin is not significantly bound to plasma proteins (less than 3%). It crosses the blood-brain barrier and is found in breast milk. The volume of distribution is 0.6-0.8 L/kg.
Metabolism
Gabapentin is not metabolized in humans and does not induce or inhibit hepatic enzymes. This characteristic makes it free from many drug-drug interactions common with other anticonvulsants.
Elimination
Gabapentin is eliminated exclusively by renal excretion as unchanged drug. The elimination half-life is 5-7 hours in patients with normal renal function. Renal clearance is directly proportional to creatinine clearance, necessitating dose adjustment in renal impairment. Gabapentin is removed by hemodialysis; supplemental doses are required after dialysis sessions.
Adverse effects
Common adverse effects include:
- Somnolence and sedation (20-30% of patients)
- Dizziness and ataxia (dose-related)
- Peripheral edema (2-8%)
- Fatigue
- Weight gain (can be significant in some patients)
- Nystagmus and diplopia
- Tremor
Gastrointestinal effects:
- Nausea
- Dry mouth
- Constipation
Neuropsychiatric effects:
- Behavioral changes in children (hostility, hyperactivity)
- Cognitive impairment, difficulty concentrating
- Increased risk of suicidal thoughts and behavior (FDA warning for all antiepileptic drugs)
- Depression
- Confusion, especially in elderly patients
Serious adverse effects
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): rare but potentially life-threatening hypersensitivity reaction
- Respiratory depression: increased risk when combined with opioids or other CNS depressants
- Withdrawal seizures: can occur with abrupt discontinuation, even in patients without epilepsy
- Rhabdomyolysis (rare)
- Sudden unexplained death in epilepsy (SUDEP) risk in epilepsy patients
Gabapentin has potential for misuse and abuse, particularly in individuals with history of substance use disorder. It is classified as a Schedule V controlled substance in some US states, though not federally scheduled.
Contraindications and warnings
Contraindications
- Known hypersensitivity to gabapentin or any component of the formulation
Warnings and precautions
Renal impairment: Dose reduction is mandatory in patients with reduced creatinine clearance. Accumulation can lead to excessive sedation and other adverse effects.
Abrupt discontinuation: Gabapentin should be tapered gradually over at least one week to minimize withdrawal symptoms and risk of seizures. Withdrawal can occur even in patients taking gabapentin for non-epileptic indications.
Suicidality: The FDA requires a warning for all antiepileptic drugs regarding increased risk of suicidal thoughts and behavior. Patients should be monitored for emergence of depression, behavioral changes, or suicidal ideation.
Respiratory depression: Serious breathing difficulties can occur, especially when combined with opioids or in patients with underlying respiratory conditions. The FDA issued a warning in 2019 regarding this risk.
CNS depression: Caution in patients performing tasks requiring alertness (driving, operating machinery), especially during initiation or dose increases.
Pregnancy: Category C. Animal studies show developmental toxicity. Use only if benefit outweighs risk. Gabapentin is excreted in breast milk; benefits of breastfeeding should be weighed against potential infant exposure.
Elderly patients: Increased sensitivity to CNS effects and higher likelihood of renal impairment requiring dose adjustment.
Tumorigenic potential: Animal studies showed increased incidence of pancreatic acinar cell tumors, but human relevance is unknown.
Drug interactions
Gabapentin has relatively few drug interactions due to lack of hepatic metabolism and protein binding.
Pharmacokinetic interactions
Antacids containing aluminum and magnesium: Reduce gabapentin bioavailability by approximately 20%. Gabapentin should be taken at least 2 hours after antacid administration.
Morphine: Increases gabapentin AUC by 44% and may increase morphine levels as well. This combination increases risk of CNS and respiratory depression.
Naproxen: May increase gabapentin absorption.
Cimetidine: Reduces renal clearance of gabapentin, increasing plasma levels.
Pharmacodynamic interactions
CNS depressants (opioids, benzodiazepines, alcohol, sedating antihistamines): Additive sedation and respiratory depression. The combination with opioids carries significant risk and requires careful monitoring.
Other anticonvulsants: Generally well-tolerated in combination therapy. No significant pharmacokinetic interactions with phenytoin, carbamazepine, valproic acid, or phenobarbital.
Notable non-interactions
Gabapentin does not interact with:
- Oral contraceptives
- Warfarin
- Digoxin
- Most other medications metabolized by cytochrome P450 enzymes
This favorable interaction profile makes gabapentin useful in patients on complex medication regimens.
Clinical pearls
Dose titration strategy: Start low and titrate slowly to minimize dizziness and somnolence. The saturable absorption mechanism means that dividing daily dose into three times daily administration maximizes bioavailability.
Renal dosing is essential: Always calculate creatinine clearance and adjust dose accordingly. Failure to do so is a common cause of excessive sedation in hospitalized patients.
Withdrawal syndrome: Even patients taking gabapentin for pain (not seizures) can experience withdrawal symptoms including anxiety, insomnia, nausea, sweating, and pain. Taper over 1-2 weeks minimum.
Limited abuse potential, but real: Gabapentin misuse is increasingly recognized, particularly among individuals with opioid use disorder who report it potentiates opioid effects or reduces withdrawal symptoms.
Not a GABA drug: Despite the name and structure, gabapentin does not work through GABAergic mechanisms. This is a high-yield exam fact.
Hemodialysis: Patients on hemodialysis require supplemental dosing after each dialysis session as gabapentin is dialyzable.
Neuropathic pain vs. nociceptive pain: Gabapentin is effective for neuropathic pain (burning, shooting, tingling) but not effective for typical nociceptive pain (inflammatory, mechanical). This distinction is clinically important.
Pregnancy registry: Patients who become pregnant while taking gabapentin should be encouraged to enroll in the North American Antiepileptic Drug Pregnancy Registry.
False-positive urine protein: Gabapentin can cause false-positive readings with some urine dipstick tests for protein. Sulfosalicylic acid precipitation procedure is recommended for verification.
Comparison with pregabalin: Pregabalin is a related gabapentinoid with linear absorption kinetics (not saturable), allowing twice-daily dosing and more predictable dose-response. Pregabalin is a Schedule V controlled substance federally.
Practice questions
1. A 62-year-old man with type 2 diabetes mellitus and chronic kidney disease (CrCl 25 mL/min) presents with burning pain in both feet consistent with diabetic peripheral neuropathy. His physician prescribes gabapentin 300 mg three times daily. Two weeks later, he returns with severe drowsiness, confusion, and difficulty walking. What is the most likely explanation?
2. A 45-year-old woman with postherpetic neuralgia is started on gabapentin. Her physician explains that despite its name and structural similarity to GABA, gabapentin does not work through GABAergic mechanisms. Which of the following best describes gabapentin's mechanism of action?
3. A 58-year-old man taking gabapentin 900 mg three times daily for neuropathic pain also takes aluminum hydroxide antacid for heartburn. He reports that his pain control has worsened recently. What advice should be given?
Frequently asked questions
How does gabapentin work?
Gabapentin binds to the α2δ-1 subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx at presynaptic nerve terminals. This decreases the release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. Despite being structurally similar to GABA, gabapentin does not bind to GABA receptors or affect GABAergic transmission. This mechanism reduces neuronal hyperexcitability in conditions like neuropathic pain and epilepsy without directly affecting normal neurotransmission.
What are the side effects of gabapentin?
The most common side effects of gabapentin include dizziness, somnolence, peripheral edema, fatigue, and ataxia. Weight gain can occur and may be significant in some patients. Neuropsychiatric effects include cognitive impairment, behavioral changes (especially in children), and increased risk of suicidal thoughts. Serious but rare adverse effects include DRESS syndrome, respiratory depression (particularly when combined with opioids), and withdrawal seizures if stopped abruptly. Elderly patients and those with renal impairment are at higher risk for adverse effects.
Is gabapentin a controlled substance?
Gabapentin is not a federally controlled substance in the United States, but several states have classified it as a Schedule V controlled substance due to concerns about misuse and abuse potential. The drug is increasingly misused, particularly by individuals with opioid use disorder who report it enhances opioid effects or reduces withdrawal symptoms. While gabapentin's abuse potential is lower than that of benzodiazepines or opioids, clinicians should be aware of misuse risk and monitor vulnerable patients accordingly.
Gabapentin vs pregabalin — what is the difference?
Both gabapentin and pregabalin are gabapentinoids that bind the α2δ-1 subunit of voltage-gated calcium channels and have similar indications for neuropathic pain and seizures. The key difference is pharmacokinetics: pregabalin has linear, dose-proportional absorption while gabapentin uses a saturable transport system with decreasing bioavailability at higher doses. Pregabalin can be dosed twice daily with more predictable efficacy, whereas gabapentin requires three times daily dosing for optimal absorption. Pregabalin is federally scheduled (Schedule V) while gabapentin is not, and pregabalin is generally more expensive.
Why does gabapentin need dose adjustment in kidney disease?
Gabapentin is eliminated exclusively through renal excretion as unchanged drug without any hepatic metabolism. Its renal clearance is directly proportional to creatinine clearance. In patients with reduced kidney function, gabapentin accumulates, leading to prolonged half-life and increased risk of adverse effects such as excessive sedation, confusion, and ataxia. Dose reduction based on creatinine clearance is mandatory to prevent toxicity. Patients on hemodialysis require supplemental doses after dialysis sessions because gabapentin is effectively removed during dialysis.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N02BF01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.